Leading Company
in Cell Therapy
Cell2in Inc. is founded by outstanding R&D experts in Korea. Our mission is to select and produce high quality cells for more patients in need of stem cell therapeutics. After a series of researches, we have developed the world’s first cell quality measurement, and established the platform technology.
The cell therapy market is rapidly increasing, but poor-quality cellular therapy products in global market are unmet therapeutic needs of age-related chronic inflammatory degenerative diseases such as asthma, osteoarthritis and idiopathic pulmonary fibrosis.
Cell2in Inc. aims to solve its inconsistent and low therapeutic effects due to poor cell quality management system.
Company
Profile
- Corporate name
- Cell2in Inc.
- CEO
- Heun Soo Kang
- Date of foundation
- February 2016
- Sales
- KRW 500 million (2021)
- Capital
- KRW 158 million
- Number of employees
- 20
- Address
- 14F, 190, Yulgok-ro, Jongno-gu, Seoul
- Business areas
- Cell therapy research and development
History
-
2022
- IND filing for asthma treatment
- GMP facilities
- ISO 9001 Quality Operation System certified
- FreSHtracer technology certified by Institut Pasteur Korea
-
2021
- Global corporate collaboration project
- Technology assessment, rated AAA (KIPA)
-
2020
- Published in Sci Adv, Clin Med, and Dermatol Sci Journal with FreSHtracer
- Patent granted for cell quality measurement & Quality improvement (Korea)
-
2019
- Published in IJSC journal with Monitoring glutathione dynamics and heterogeneity in living stem cells
- Patent granted for FreSHtracer technology (U.S.)
- Clinical trial of cell therapy for pets
-
2018
- Published in Stem Cell Report journal with FreSHtracer technology
- Published in JCI journal with FreSHtracer
- Presentation of FreSHtracer platform technology (ISSCR)
-
2017
- Presentation of FreSHtracer platform technology (KSSCR)
- Biomedical technology development project
- Family Company of Korea research institute of bioscience & biotech awarded
-
2016
- Cell2in Inc. Established
- Certificated as a Venture Company
- Corporate Research Institute designated